Expert InterviewGPCR
Slingshot members are talking to an expert! The topic is:
Looking at the Future of Oral Weight Loss Medications, Including Structure Therapeutics recent Phase 2 data on Aleniglipron and the Uptake of Novo Nordisks Wegovy
Executed on:Apr 9, 2026 9:30 AM EDT
Call Duration:30 minutes
Expert Profile
ExpertBlinded Expert
Institution: University of California at San Diego
- Board-certified Obesity Medicine Physician and Medical Director for the Weight Management Program at UC San Diego Health
- Treats over 100 patients per year with obesity with a variety of methods including surgery, medication, nutrition, behavior, and lifestyle support.
- Clinical interest in metabolism, weight regulation, treatment of obesity and weight-related medical conditions; Research interests include anti-obesity medications, obesity medicine education and bariatric surgery.
Interview Goal
The goal of this consultation is to assess the clinical and commercial potential of Structure Therapeutics’ oral GLP-1 receptor agonist, aleniglipron, based on Phase 2 ACCESS-II data. The discussion will also explore how physicians view the role of aleniglipron within the evolving obesity and Type 2 diabetes treatment landscape, including its potential positioning versus established agents, expected patient demand, and likelihood of adoption in real-world practice. Also looking at the current update of oral Wegovy from Novo Nordisk.